The price of Reata Pharmaceuticals Inc. (NASDAQ:RETA) shares last traded on Wall Street fell -0.96% to $165.58.
Based on available information, 10 analysts follow Reata Pharmaceuticals Inc. (NASDAQ:RETA). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $173.00 and a low of $172.00, we find $172.50. Given the previous closing price of $167.19, this indicates a potential upside of 3.18 percent. RETA stock price is now 66.14% away from the 50-day moving average and 142.79% away from the 200-day moving average. The market capitalization of the company currently stands at $4.04B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
Among analysts, 9 rate the stock a hold while 1 rate it a buy. Brokers who have rated the stock have averaged $172.45 as their price target over the next twelve months.
With the price target of $140, TD Cowen recently initiated with Outperform rating for Reata Pharmaceuticals Inc. (NASDAQ: RETA).
In other news, Anand Bhaskar, SVP, Chief Accounting Officer sold 2,343 shares of the company’s stock on Jun 14. The stock was sold for $239,248 at an average price of $102.11. Upon completion of the transaction, the SVP, Chief Accounting Officer now directly owns 24,898 shares in the company, valued at $4.12 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 13, COO, CFO and President Soni Manmeet Singh sold 78,085 shares of the business’s stock. A total of $8,034,343 was realized by selling the stock at an average price of $102.89. This leaves the insider owning 58,376 shares of the company worth $9.67 million. Insiders disposed of 469,186 shares of company stock worth roughly $77.69 million over the past 1 year. A total of 3.83% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in RETA stock. A new stake in Reata Pharmaceuticals Inc. shares was purchased by PERCEPTIVE ADVISORS LLC during the first quarter worth $359,189,000. DEEP TRACK CAPITAL, LP invested $120,708,000 in shares of RETA during the first quarter. In the first quarter, POINT72 ASSET MANAGEMENT, L.P. acquired a new stake in Reata Pharmaceuticals Inc. valued at approximately $60,288,000. HOLOCENE ADVISORS, LP acquired a new stake in RETA for approximately $50,456,000. SOLEUS CAPITAL MANAGEMENT, L.P. purchased a new stake in RETA valued at around $28,909,000 in the second quarter. In total, there are 249 active investors with 89.30% ownership of the company’s stock.
A candlestick chart of Reata Pharmaceuticals Inc. (NASDAQ: RETA) showed a price of $165.51 on Monday morning. During the past 12 months, Reata Pharmaceuticals Inc. has had a low of $18.47 and a high of $167.24. The fifty day moving average price for RETA is $101.33 and a two-hundred day moving average price translates $68.91 for the stock.
The latest earnings results from Reata Pharmaceuticals Inc. (NASDAQ: RETA) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$3.14, missing analysts’ expectations of -$2.42 by -0.72. This compares to -$2.03 EPS in the same period last year. The company reported revenue of $0.2 million for the quarter, compared to $0.91 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -78.67 percent. For the current quarter, analysts expect RETA to generate $120k in revenue.
Reata Pharmaceuticals Inc.(RETA) Company Profile
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich’s ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.
